Psoriasis News and Research

Latest Psoriasis News and Research

Study examines impact of EHR on childhood obesity evaluation

Electronic health records and embedded tools can alert and direct pediatricians so they can better manage the weight of children and teenagers, according to a new Kaiser Permanente study published online in The Journal of Pediatrics.

22 Feb 2012

Valeant receives FDA approval for secondary supplier of Methoxsalen

The FDA has approved the addition of a secondary supplier of Methoxsalen USP, an integral component of a treatment for the relief of moderate to severe psoriasis prescribed under the brand name Oxsoralen-Ultra (methoxsalen) Capsules, USP, 10mg.

15 Feb 2012

Molecular secrets behind halofuginone's power

For roughly two thousand years, Chinese herbalists have treated Malaria using a root extract, commonly known as Chang Shan, from a type of hydrangea that grows in Tibet and Nepal. More recent studies suggest that halofuginone, a compound derived from this extract's bioactive ingredient, could be used to treat many autoimmune disorders as well. Now, researchers from the Harvard School of Dental Medicine have discovered the molecular secrets behind this herbal extract's power.

13 Feb 2012

New combination laser therapy effective in treating melasma

On the surface, it would seem as though the skin condition melasma (commonly referred to as the "mask of pregnancy") and tattoos would have little in common. However, they both affect a person's skin, can be quite difficult to treat or remove and, now, dermatologists are discovering new laser therapies which enhance treatment for both conditions.

8 Feb 2012

GSK voluntarily pauses enrollment in GSK2251052 clinical trials for cUTI

Anacor Pharmaceuticals announced today that its partner GlaxoSmithKline has voluntarily paused enrollment in its current clinical trials of GSK2251052 due to a recently identified microbiological finding in a small number of patients in the Phase 2b trial of GSK '052 for the treatment of complicated urinary tract infections (cUTI).

6 Feb 2012

Pleasurability of scratching for itch relief is related to body location

New research from Gil Yosipovitch, M.D., Ph.D., professor of dermatology at Wake Forest Baptist Medical Center and a world-renowned itch expert, shows that how good scratching an itch feels is related to the itch's location.

30 Jan 2012

New consensus guidelines for treatment of plaque psoriasis

To assist the millions of Americans living with psoriasis, the most common autoimmune disease in the country, the National Psoriasis Foundation published the most recent guidelines in the United States for the management of plaque psoriasis—the most prevalent form of the disease, affecting roughly 80 percent of people with psoriasis.

26 Jan 2012

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

Johnson & Johnson today announced sales of $16.3 billion for the fourth quarter of 2011, an increase of 3.9% as compared to the fourth quarter of 2010. Operational sales increased 4.0% and the negative impact of currency was 0.1%.

24 Jan 2012

EMA CHMP issues positive opinion to MSD's REMICADE for treatment of pediatric UC

MSD today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the use of REMICADE (infliximab) in the treatment of severely active ulcerative colitis (UC) in pediatric patients ages 6 to 17 years, who have had an inadequate response to conventional therapy, including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.

21 Jan 2012

Patients with PsA may benefit from new medications and surgeries

Medications or biologic agents that target T-cells, white blood cells involved in the body's immune system, appear to offer significant benefit to patients suffering from psoriatic arthritis (PsA), a type of arthritis that affects up to 48 percent of patients with the skin disease psoriasis, according to a new review article in the Journal of the American Academy of Orthopaedic Surgeons.

19 Jan 2012

New possibilities for effective treatment of psoriasis

Researchers at Link-ping University in Sweden are now launching a plan to effectively treat psoriasis.

11 Jan 2012

Oxygen Biotherapeutics to commence study to determine efficacy of Dermacyte in relieving Histamine induced pruritus

Oxygen Biotherapeutics, Inc. has announced that enrollment for the company’s first dermatological study will begin later this month at St. John’s Medical College Hospital in Bangalore, India. The company received formal approval from the hospital’s Ethics Review Board in December. This study is the first of a series of trials scheduled for 2012 to explore the efficacy of Dermacyte to treat a variety of dermatological conditions, such as allergic contact dermatitis, psoriasis and acne.

9 Jan 2012

Cardinal Health launches infusion room management tool for community rheumatologists

Cardinal Health Specialty Solutions today launched InfusaTrack, a Web-based infusion room management tool that makes it easier for community rheumatology practices to offer in-office infusion therapy services to patients.

7 Jan 2012

Pfizer, Karo Bio partner to develop RORgamma modulators for autoimmune diseases

Karo Bio AB has entered into a research collaboration agreement with Pfizer Inc., to discover and develop novel small molecule RORgamma modulators for the treatment of autoimmune diseases.

26 Dec 2011

Enrollment complete in two Anacor's tavaborole Phase 3 trials on onychomycosis

Anacor Pharmaceuticals announced today that it has completed the enrollment of approximately 600 patients in the second of its two Phase 3 trials of tavaborole, a topical anti-fungal product candidate for the treatment of onychomycosis, a fungal infection of the nail and nail bed that affects approximately 35 million people in the United States.

23 Dec 2011

Denali Concrete Management initiates enrollment in CF101 phase 3 study for Dry Eye Syndrome

Denali Concrete Management Inc. announced today that it has commenced patient enrollment for a phase 3 clinical study of the safety and efficacy of CF101, daily administered orally, in patients with moderate-to-severe Dry Eye Syndrome.

21 Dec 2011

Menarini, Moberg Derma partner to distribute Emtrix in Italy

Moberg Derma AB has entered into a distribution agreement with Menarini Group for Emtrix - for discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis.

9 Dec 2011

Pharmacyclics, Janssen partner to develop and market PCI-32765 anti-cancer compound

Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has executed an agreement with Pharmacyclics, Inc. to jointly develop and market the anti-cancer compound, PCI-32765.

9 Dec 2011

PDUFA goal date of NDA for Protalix's taliglucerase alfa extended

Protalix BioTherapeutics, Inc., announced today that it received notification from the U.S. Food and Drug Administration (FDA) that the FDA has extended the Prescription Drug User Fee Act (PDUFA) goal date of the New Drug Application (NDA) for taliglucerase alfa to May 1, 2012, a three-month extension from the previous PDUFA date of February 1, 2012.

6 Dec 2011

Idera receives FDA notification to proceed with IMO-3100 Phase 2 clinical trial for psoriasis

Idera Pharmaceuticals, Inc. today announced the receipt of verbal notification from the Food and Drug Administration that the company may proceed with a Phase 2 clinical trial of IMO-3100 in patients with psoriasis based on a trial protocol submitted by the company in October 2011.

2 Dec 2011